These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia. Levine AC; Kirschenbaum A; Gabrilove JL Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072 [TBL] [Abstract][Full Text] [Related]
5. Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors. Elterman DS; Lawrentschuk N; Guns E; Hersey K; Adomat H; Wood CA; Fleshner N J Urol; 2010 May; 183(5):2085-9. PubMed ID: 20303529 [TBL] [Abstract][Full Text] [Related]
6. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia]. Djavan B; McConnell J Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401 [TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy for benign prostatic hyperplasia in the 90's. Ekman P J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721 [TBL] [Abstract][Full Text] [Related]
8. Drug treatment for benign prostatic hyperplasia. Several trials have shown benefit of finasteride. Collins GN BMJ; 1997 Aug; 315(7104):371. PubMed ID: 9270474 [No Abstract] [Full Text] [Related]
9. [5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia]. MMW Fortschr Med; 2002 Oct; 144(44):56. PubMed ID: 12494605 [No Abstract] [Full Text] [Related]
10. [How effective is finasteride?]. Krome S Dtsch Med Wochenschr; 2011 Feb; 136(8):354. PubMed ID: 21348003 [No Abstract] [Full Text] [Related]
13. [Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)]. Aliaev IuG; Vinarov AZ; Lokshin KL; Spivak LG Urologiia; 2006; (6):83-6. PubMed ID: 17315721 [No Abstract] [Full Text] [Related]
14. Finasteride to prevent morbidity from benign prostatic hyperplasia. Wasson JH N Engl J Med; 1998 Feb; 338(9):612-3. PubMed ID: 9475770 [No Abstract] [Full Text] [Related]
15. Finasteride in benign prostatic hyperplasia. Verhamme KM; Bosch RJ; Sturkenboom MC N Engl J Med; 2004 Mar; 350(13):1359-61; author reply 1359-61. PubMed ID: 15049034 [No Abstract] [Full Text] [Related]
16. [The current principles of the conservative treatment of patients with benign prostatic hypertrophy]. Ianev V; Milushev N Khirurgiia (Sofiia); 1994; 47(3):36-8. PubMed ID: 8531430 [TBL] [Abstract][Full Text] [Related]
17. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA; N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504 [TBL] [Abstract][Full Text] [Related]
18. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia. Agha AH; Roy JB; Culkin DJ; Lyon K Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332 [TBL] [Abstract][Full Text] [Related]
19. Finasteride in benign prostatic hyperplasia. Wysowski DK; Farinas E N Engl J Med; 2004 Mar; 350(13):1359-61; author reply 1359-61. PubMed ID: 15044649 [No Abstract] [Full Text] [Related]
20. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]